Uniphar delivers record organic growth and higher EPS as 2028 earnings target remains on track

Uniphar (LSE:UPR) reported solid preliminary results for 2025, posting revenue growth of 11.0% to €3.07 billion and a 7.0% increase in gross profit to €457.7 million. Performance was supported by organic gross profit growth of 8.9%, marking the company’s strongest organic expansion since its IPO. Growth was recorded across all divisions, led by Uniphar Pharma with a 15.5% increase and Medtech at 10.5%, while Supply Chain & Retail delivered 4.2% growth and expanded its pharmacy network to 482 locations.

EBITDA increased 6.0% year-on-year to €130.9 million, while adjusted earnings per share rose 21% to 24.8 cent. The improvement was aided by reduced finance costs and a €35 million share buyback programme, which saw the company repurchase 13.4 million shares. Uniphar ended the period with net bank debt of €171.1 million and leverage of 1.6x, alongside extended credit facilities and free cash flow conversion of 99.1%. Management reiterated confidence in achieving its €200 million EBITDA target by 2028, supported by ongoing strategic investments including a new advanced distribution hub in Ireland and expanded digital capabilities following the acquisition of TouchStore.

The group also reported continued progress on sustainability goals, highlighting a 29.9% reduction in Scope 1 and 2 emissions since 2019. Uniphar maintained strong ESG credentials, including an MSCI ‘AAA’ rating and a low-risk industry assessment from Sustainalytics. For shareholders, the board proposed a total dividend of €5.2 million, representing a 5.2% increase on a per-share basis. Management noted positive trading momentum heading into 2026 and expects growth to remain largely organic in line with its medium-term outlook.

More about Uniphar PLC

Uniphar plc is a Dublin-headquartered international healthcare services provider working with more than 200 multinational pharmaceutical and medical technology manufacturers. Through its Pharma, Medtech, and Supply Chain & Retail divisions, the group operates across Europe, North America, APAC and the MENA region, supplying products to over 160 countries. The company focuses on improving patient access to pharmaceutical and medical technologies by connecting manufacturers with healthcare providers while leveraging scale to drive growth and profitability.